Syfovre (pegcetacoplan injection, for intravitreal use)

Syfovre (pegcetacoplan injection) is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Ziextenzo (pegfilgrastim-bmez injection)

Ziextenzo (pegfilgrastim-bmez) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non¬myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Ziextenzo is biosimilar to Neulasta (pegfilgrastim).

Udenyca (pegfilgrastim-cbqv injection)

Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend (pegfilgrastim-fpgk)

Stimufend (pegfilgrastim-fpgk) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Sylatron (peginterferon alfa-2b)

PegIntron and Rebetol Combo Pack (peginterferon alfa-2b and ribavirin combo pack)

PegIntron (peginterferon alfa-2b injection)

PegIntron (peginterferon alfa-2b) is an interferon used to treat chronic hepatitis C in patients with compensated liver disease.

Plegridy (peginterferon beta-1a injection for subcutaneous use)

Plegridy (peginterferon beta-1a) Autoinjector is an interferon beta-1a used to treat patients with relapsing forms of multiple sclerosis.

Somavert (pegvisomant)

Somavert (pegvisomant) is a manufactured protein similar to human growth hormone (HGH) used for the treatment of acromegaly (a growth disorder caused by too much growth hormone).

Pemazyre (pemigatinib tablets)

Pemazyre (pemigatinib) is a kinase inhibitor used to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.